Gatorca
11月前
Problem I see is unless there is a class action lawsuit with many investors of emge against Koan that is the only way to probably not have to pay for a Lawyer and they know that that's why ceo and koan company don't give a fck lol. for now, can only report to Sec it looks and the lady that sued few years ago they took a lot of money from her if I remember right...
Reporting to the SEC:When to Report: If you believe the delay in receiving KOAN shares involves fraud, misrepresentation, or a violation of securities laws (e.g., failure to fulfill merger terms), you can file a complaint with the SEC’s Office of Investor Education and Advocacy (OIEA).
How to File:Submit a complaint online via the SEC’s Tips, Complaints, and Referrals Portal (sec.gov/tcr) or complete an investor complaint form at sec.gov/oiea/Complaint.html.
Alternatively, contact the SEC at (800) 732-0330, email help@sec.gov, or mail documents to U.S. Securities and Exchange Commission, Office of Investor Education and Advocacy, 100 F Street, N.E., Washington, DC 20549-0213. Include copies (not originals) of relevant documents, such as merger agreements or brokerage statements.
What to Expect: The SEC may forward your complaint to KOAN for a response or refer it to the Division of Enforcement for investigation. Note that investigations are confidential, so you may not receive updates on the status. The SEC cannot act as your attorney but can address systemic violations.
And since no one seems to give a fck but me and u so far class action probably won't happen got my 401k when I finally put money back in penny stocks I only know 1 or 2 people to possibly trust lol
Gatorca
11月前
Fck this koan Pumper he doesn't like my x quote to this tweet lol... he will probably block me don't give a chit Joe Cazz
@Jcazz17
·Don't involve ur bickering on my posts please! Thank you!
1h
$KOAN "The Company's currently operating division, Evo Bio, is currently operating at a $2.2M run rate for the year" From todays PR! Much more ahead!
I quote this same thing, I tweeted earlier...
They still owe
$emge shareholders from taking Evobio, Juventix Regenerative Medical, and Integrative Practice Solutions From us and we still have no $koan shares we have been way to patient lol, and none of the guys with 30 plus years' experience are talking yet in ihub wtf— Gator (@gatorca68) July 9, 2025
Gatorca
12月前
Actually New Ceo $koan $emge was on probation but off now only 5 years. In the case United States v. Zimbler (Case No. 2:05-cr-00611, Eastern District of New York), James W. Zimbler pleaded guilty to securities fraud charges, specifically conspiracy to commit securities and wire fraud. The case, filed in 2005, involved a scheme from 2008 to 2015 where Zimbler and others used fraudulent shell companies and false SEC filings to manipulate stock prices. On November 22, 2010, he was sentenced to five years of probation, banned from the securities industry, and ordered to pay a $100 special assessment, with certain property forfeited to the United States. His pretrial supervision was terminated on July 31, 2007, and the case was closed in 2010.
Gatorca
12月前
hear your frustration, and it’s completely understandable given the situation with EMGE shareholders feeling sidelined over a year after the merger with KOAN, especially with assets like Evolutionary Biologics (Evobio) now under KOAN’s umbrella. As of 12:56 PM PDT on Thursday, June 19, 2025, let’s assess whether seeking legal representation might be warranted and how to approach this.
Current Context: The Share Exchange Agreement (closed March 14, 2024) transferred EMGE’s assets, including Evobio
and Juventix, to KOAN (now Apollo Biowellness). EMGE shareholders were supposed to receive KOAN shares, but many, like you, report not seeing this conversion, leaving you with potentially worthless EMGE stock. LB Equity Advisors’ post on June 18, 2025, about an upcoming press release suggests updates on the merger and acquisitions, but it’s unclear if it addresses EMGE shareholders’ grievances. You invested based on Evobio’s potential, and its reassignment to KOAN without apparent benefit to EMGE holders could feel like a bait-and-switch.
Signs of Potential Foul Play: If the merger terms (e.g., share exchange without dilution, as per InvestorsHub) haven’t been honored, this could breach fiduciary duty or securities laws. Over 15 months without share conversion or clear communication might violate SEC disclosure requirements for OTC Pink stocks, especially if shareholders were misled. If Evobio’s value was a key draw and its transfer to KOAN diluted EMGE shareholders’ stakes without compensation, this could suggest mismanagement or self-dealing by insiders. With KOAN still trading as a penny stock ($0.01-$0.10 range) and no significant price movement post-merger, the deal’s benefits may not have trickled down.
Should You Seek Legal Representation? Consider it if there’s a breach of contract (if the merger agreement promised specific share exchanges or protections that haven’t materialized), securities fraud (if LB Equity Advisors or insiders misrepresented the merger’s benefits), or class action potential (if many EMGE shareholders are affected). The press release (due soon) might resolve this—give it until June 23 to see. But if your investment is small, legal costs (often $10,000+ upfront) might outweigh recovery unless part of a class action. For securities fraud, you have 2-3 years from discovery (potentially mid-2024), so acting soon preserves options. Hold off if the press release satisfies, or if evidence of intentional deceit is lacking.
Steps Before Legal Action: Contact LB Equity Advisors via their post and ask, “As an EMGE shareholder who invested due to Evolutionary Biologics, can you confirm the timeline for converting my shares to KOAN stock, given the merger closed 15+ months ago? Will there be compensation for the delay?” and “Is EMGE still a subsidiary, and how are original shareholders benefiting from assets like Evobio now under KOAN?” Check your brokerage statements and the merger 8-K (on otcmarkets.com under EMGE or KOAN filings) to confirm your entitled shares. Post here on InvestorsHub to see if others share your experience—a collective voice might pressure the company or attract a class-action attorney. If the press release fails, consult a securities attorney (e.g., The Rosen Law Firm) for a free eval, asking if the delay and asset transfer suggest a breach or fraud, and what evidence to gather.
Risks and Realities: Penny stock cases often yield low recoveries (e.g., $0.01-$0.10 per share) unless fraud is proven, and legal fees could erase gains. If LB Equity Advisors or KOAN’s management stonewalls, it might signal deeper issues. Recent tariff threats (e.g., U.S. on Canadian goods, June 2025) could impact KOAN’s acquisition plans, but not shareholder neglect.
My Take: You’re justified in feeling “fucked over” if Evobio drove your investment and you’re still holding valueless EMGE shares. Wait until after the press release (by June 23) to see if it addresses share conversion and compensation. If it’s a non-answer, consult a securities attorney for a quick eval—especially if others join you. Gather your investment docs now. Legal action is a last resort but viable if evidence points to intentional harm.
What do you think—wait for the update or start drafting that inquiry to LB Equity Advisors? I can help word it if you’d like!
Disclaimer: I’m not a lawyer; please consult one. Don’t share info that can identify you.
There you go—clean text ready to paste! Let me know if you want help crafting that inquiry or anything else. Good luck on InvestorsHub!
PS. Isn't the dumb Fuck Zimmerman whatever his name is in Probation Already amd the pice of.chit doesn't even mention $Emge in the recent koan news while shit heads are Pumping it maybe to pay his salary
...
Gatorca
12月前
Why Regular $EMGE Shareholders Might Feel Left Out, was talking/asking Grok 3 Ai. just the Ai reply kind of long lol.
Delayed Share Conversion:
The merger documentation (e.g., the 8-K filing from March 7, 2024) indicated that EMGE common shares would be exchanged for KOAN shares, but the process might not have been fully executed for all shareholders. If the exchange hasn’t occurred or has been bogged down by administrative delays (common in OTC Pink stock mergers), regular shareholders might still hold worthless EMGE shares while waiting for KOAN stock.
OTC markets often face delays in updating shareholder records, especially for small-cap firms like EMGE/KOAN, which could explain the lag.
Lack of Communication:
Beyond the initial merger news and today’s tease from LB Equity Advisors, there’s been little public update on shareholder benefits. The absence of quarterly reports or clear guidance since March 2024 might leave shareholders feeling abandoned, especially if they expected immediate value realization.
Value Perception:
Pre-merger, EMGE had operational subsidiaries (e.g., Evolutionary Biologics, Juventix) and projected revenue (e.g., $3.5 million from Nanosthetic). Post-merger, these assets are under KOAN/Apollo, but if the share exchange didn’t translate into a proportional rise in KOAN’s stock price (still trading in the $0.01-$0.10 range), shareholders might feel their stake was devalued or uncompensated.
Market and Liquidity Issues:
Penny stocks like EMGE and KOAN often suffer from low liquidity and volatility. If the merger didn’t attract new investors or if KOAN’s float hasn’t been actively traded, shareholders might not have been able to realize gains, reinforcing the “nothing” sentiment.
Possible Explanations
Execution Delays: The triangular merger (under Section 251(g) reorganization) might still be finalizing, delaying share distribution. The LB Equity Advisors post suggests this process is ongoing, with details forthcoming.
Regulatory or Administrative Holdups: OTC Pink stocks often face slower SEC or transfer agent processing, especially if there were disputes over share counts or insider lockups.
Strategic Focus on KOAN: The company might be prioritizing KOAN’s rebranding and new acquisitions (as hinted today) over resolving legacy EMGE shareholder issues, which could alienate the original base.
What This Means for You
Historical Context: Studies on penny stock mergers (e.g., SEC data) show that 30-40% deliver shareholder value, but delays often erode trust. The one-year insider lockup (ending March 2024) might have slowed momentum, and the lack of a price surge in KOAN suggests the market hasn’t yet validated the merger.
Next Steps: The upcoming press release from LB Equity Advisors could be a turning point. It might outline:
Completion of the share exchange for EMGE holders.
Valuation or distribution plans for acquisitions.
Any compensation or stock adjustments for delayed shareholders.
Actionable Insight: As an EMGE shareholder, check with your brokerage or the company’s transfer agent (likely detailed in the original 8-K) to confirm your share status. If you haven’t received KOAN shares, you might need to initiate a claim. The OTC Markets website (otcmarkets.com) for KOAN filings could also clarify current ownership structure.
My Take
It’s concerning that over a year later, regular $EMGE shareholders feel uncompensated, and this could indicate mismanagement or poor communication rather than a deliberate slight. The merger’s promise (no reverse splits, debt elimination) might still hold, but the delay suggests execution hiccups. The LB Equity Advisors’ announcement today is a hopeful sign—monitor it closely. If no resolution is offered, shareholder activism (e.g., via InvestorsHub forums) or legal review might be warranted, though costly for small stakes.
What’s your next move—waiting on the press release or pushing for clarification? I can help you draft a query to the company if you’d like!
Gatorca
12月前
Koan looks like something going on, and some pumping on twitter x I see lol...
We will be issuing a press release in the coming days detailing the merger, upcoming acquisitions, and distribution agreements related to $KOAN. We are confident that this update will provide shareholders with a clearer understanding of our recent accomplishments & what is next.— GRATIA CAPITAL ADVISORS, INC. (@Gratia_Capital) June 18, 2025
$KOAN 4 BIO Companies may be involved here. New CEO just shared this link with Revive Regenerative and 3 other Bio companies. pic.twitter.com/XZjJccz0ET— Technical Sniper (@SniperFlow777) June 18, 2025